Small Molecule NF-κB Pathway Inhibitors in Clinic

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Nuclear factor kappa B (NF-κB) signaling is integral to numerous human chronic diseases.
• Its role in gene transcription is well-documented, driving research into pathway modulation for therapeutic interventions.

Purpose of the Study:

• To review clinically relevant small molecule inhibitors of the NF-κB pathway.
• To identify underexplored targets within the NF-κB pathway with potential for clinical success.

Main Methods:

• Literature review of small molecule inhibitors targeting NF-κB.
• Analysis of NF-κB pathway from cell surface stimulation to nuclear signaling.
• Identification of potential therapeutic targets.

Main Results:

• Numerous small molecules targeting NF-κB are in clinical trials or on the market.
• Repurposing of existing drugs with NF-κB activity is a growing trend.
• Small molecules represent a significant portion of recent FDA approvals.

Conclusions:

• Small molecule inhibitors of the NF-κB pathway offer significant therapeutic potential.
• Further exploration of underexplored NF-κB targets could yield novel treatments.
• Targeting NF-κB remains a promising strategy for chronic disease management.